37642-55-0Relevant academic research and scientific papers
Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors
Haning, Helmut,Niewoehner, Ulrich,Schenke, Thomas,Lampe, Thomas,Hillisch, Alexander,Bischoff, Erwin
, p. 3900 - 3907 (2007/10/03)
Several different heterocyclic systems were compared as PDE5 inhibitor scaffolds. In addition to the known 3H-imidazo[5,1-f][1,2,4]triazin-4-ones and pyrazolopyrimidinones, isomeric imidazo[1,5-a][1,3,5]triazin-4(3H)-ones were also shown to be potent and selective PDE inhibitor scaffolds with in vivo activity. SAR trends were elucidated for sulfonamide derivatives with generality across different scaffolds.
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
-
Page 18, (2010/02/09)
The invention provides compounds of Formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein A, P, J, x, and R10 are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including, diabetes, including type 1 and type 2 diabetes, hyperglycemia, dyslipidemia, impaired glucose tolerance, metabolic syndrome, and/or cardiovascular disease.
